The Cancer Center at CARES is now participating in a clinical trial to evaluate the effectiveness of a novel medication designed to improve the quality of life of cancer patients treated with chemotherapy. The study medication being evaluated has been tested in previous studies and found to be safe in canine cancer patients at the doses administered in the current study.
To qualify for the study,
(1) Patients must be dogs that have a confirmed diagnosis of sarcoma. This includes tumor types such as hemangiosarcoma, osteosarcoma, and histiocytic sarcoma.
(2) Patient should not have prior chemotherapy treatment within the past 2-4 weeks.
(3) Treatment recommendations must include Doxorubicin (Adriamycin) chemotherapy treatment given once every 2 weeks for at least 4 treatments.
(4) Patients must be healthy enough to undergo treatment.
Owners must be willing and able to
(1) Understand and sign the informed consent.
(2) Bring their pets to CARES for treatment appointments for approximately 10 weeks.
(3) Give oral medications at home as per the study schedule.
(4) Maintain a daily quality of life journal provided by the study.
Benefits of participation in the trial include financial compensation up to $690, standard-of-care treatment provided to the patient, the potential of benefit from the drug being evaluated, and the opportunity to improve the lives of future cancer patients who will benefit from the knowledge gained by this study.
To schedule an appointment to discuss participation and determine whether your pet qualifies, please call (215) 750-2774.